The Defence Research and Development Organisation (DRDO), which developed 2-Deoxy-D- Glucose (2-DG), a drug used for treatment of Covid-19 patients, has called for Expression of Interest (EoI) to transfer the technology to Indian pharmaceutical industries for production.